Sign in

You're signed outSign in or to get full access.

Brian P. Skorney

Senior Research Analyst and CFA at Baird

Brian P. Skorney is a Senior Research Analyst and CFA at Baird, specializing in biotechnology equity research. He covers key companies including Soleno, Sarepta, Lexeo, Enanta, Crinetics, Vertex, and Xenon, with a strong performance track record that includes ranking No. 75 on TipRanks' Top 100 Wall Street analysts list in 2019 and No. 3 stock picker in Biotechnology by Thomson Reuters Analyst Awards (StarMine) in 2016. Skorney joined Baird in 2012 after serving as senior vice president in equity research at Brean Murray Carrett & Co., vice president at ThinkEquity, LLC, research analyst at Susquehanna International Group, LLC, and lab manager at the Howard Hughes Medical Institute. He holds a BS in Biological Sciences from the University of Notre Dame and an MBA in Finance from New York University.

Brian P. Skorney's questions to BIOGEN (BIIB) leadership

Question · Q4 2025

Brian P. Skorney asked about the commercial opportunity for BIIB080, an anti-tau ASO, considering the challenges faced by Leqembi as an IV, and what specific clinical data would be necessary to achieve a higher level of commercial success.

Answer

Christopher A. Viehbacher, President and CEO, Biogen, highlighted the neurology community's interest in tau as a target and BIIB080's ability to reduce tau. He emphasized the need to see the data on cognition and side effect profile, noting that positive results would excite the community but would still require a multi-year Phase III program. He also mentioned the potential for BIIB080 in other tauopathies and its role in a multi-modality approach to Alzheimer's.

Ask follow-up questions

Fintool

Fintool can predict BIOGEN logo BIIB's earnings beat/miss a week before the call